Does Celsion stock have a way to run yet?
Despite the recent market-wide pullback, oncology drug-maker Celsion (CLSN) is enjoying a breakout year, with shares up by 210% year-to-date. One Street analyst thinks the stock has a way to run yet.
Why is Celsion Corp (clsn) stock trading higher Tuesday?
Celsion Corp (NASDAQ: CLSN) shares are trading higher Tuesday as traders circulate a Zacks Small-Cap Research note with a $37 valuation target on the stock. Zacks analyst David Bautz highlighted the business update Celsion provided at the end of March.
Why are share prices going down?
High inflation, rising interest rates, and the threat of recession might be gone soon or they might be with us for a while. But at times like this, understanding why share prices are going down makes it that bit easier to wait for the storm to pass. Make no mistake… inflation is coming.
Why did the stock market drop like it did yesterday?
L ately, when the stock market indices fall like it did yesterday, we are told that it is because of the omicron variant. While covid-sensitive areas of the market such as airlines and cruise stocks did fall, yesterday’s drop was led by tech stocks that have so far been resilient to these recent declines.
Is celsion Corp a good stock to buy?
Celsion has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
What does celsion Corp do?
Celsion Corporation is a fully integrated oncology company with a high-potential portfolio of innovative cancer treatments. With platform technologies in chemotherapy and gene-mediated immunotherapy, and RNAi engineered to enhance the clinical benefits of proven agents, Celsion's mission is transformational.
What is Clsn?
LAWRENCEVILLE, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced it would highlight its PLACCINE platform technology in an oral presentation at the World Vaccine Congress taking place in ...
What is ThermoDox?
Lyso-thermosensitive liposomal doxorubicin (ThermoDox®), as used in the current study, is a heat-activated liposomal formulation of doxorubicin that facilitates targeted delivery to tumor/tissue volumes at temperatures exceeding 40°C.
3 Penny Stocks Insiders Are Buying
Celsion (CLSN) COVID Vaccine Effective in Pre-Clinical Studies
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision.
Celsion's Vaccine Platform Shows Potential Against COVID-19 In Preclinical Studies
Celsion (CLSN) announces data from pre-clinical studies for its investigational vaccine platform as a potential treatment for COVID-19.
Disney is moving over 2,000 corporate jobs from California to Florida to save millions
Celsion Corporation (NASDAQ: CLSN) has announced results from preclinical in vivo studies of its next-generation PLACCINE DNA vaccine platform. Data showed that the vaccine candidate produced antibodies and cytotoxic T-cell response specific to the spike antigen of SARS-CoV-2 in animal models.
How is DoorDash a 62 billion company?
Walt Disney Co. announced plans last week to move approximately 2,000 jobs from California to Florida and will reap a nearly $580 million tax break in the process.
Chinese stock bloodbath continues, with BABA, Tencent still showing no signs of life. Can we buy in yet?
I am interested in hearing a bull case for doordash. I've seen many youtube videos, reddit posts, articles on why this stock is overvalued at 18 price to sales ratio which implies at least 20-25% sales growth (sales growth 6-9x) for the next 10 years based on my model.
NVIDIA earnings coming up on Monday
It's looking brutal for both of the big Chinese names. The education stocks we of course have to dismiss from the get-go, they're done. However the jury is still out on BABA and Tencent. This can be a generational buying opportunity if China lets them do business somewhat freely even after the crackdown.
